Developmental outcome of preterm infants after surfactant therapy: systematic review of randomized controlled trials.
OBJECTIVE
To review neuro-developmental outcome at 1 and 2 years of age following randomized controlled trials (RCT) of neonatal surfactant therapy.


METHODS
A systematic review of the MEDLINE, Embase and Cochrane Controlled Trial Register databases, searching for RCT of surfactant replacement therapy with follow-up outcomes, was carried out. The main outcome measures were severe and mild disability at 1 and 2 years plus composite adverse outcome of death and/or severe disability.


RESULTS
A meta-analysis using odds ratios was carried out on 13 RCT. There were a total of 2218 treated and 2090 control infants who underwent follow up at 1 year of age. There were 303 treated and 292 control infants with follow up at between 18 months and 2 years of age. Surfactant therapy was associated with a lower rate of mild disability at 1 year (OR 0.79; 95% CI 0.66-0.95). There was a reduction in the combined adverse outcome (death or severe disability rate) at 1 year (OR 0.8; 95% CI 0.72-0.89). Neither the 1 year nor the 2 year follow-up examination showed a statistical difference in the severe disability rate between the control and treated group.


CONCLUSIONS
Surfactant therapy increases survival without an increase in subsequent morbidity at 1 and 2 years of age.
Sinn
J K H
JK
Westmead Hospital and Centre for Perinatal Health Services Research, University of Sydney, New South Wales, Australia. johnsinn@westgate.wh.usyd.edu.au
Ward
M C
MC
Henderson-Smart
D J
DJ
D002675:Child, Preschool; D002658:Developmental Disabilities / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D011663:Pulmonary Surfactants / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D011663:Pulmonary Surfactants